Source-grounded facts extracted from EXOZYMES INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EXOZYMES INC. entered into Warrant Agent Agreement with VStock Transfer, LLC valued at Warrants to purchase shares of Common Stock issued pursuant to the agreement. (effective 2026-06-05).
“The Warrants were issued pursuant to a Warrant Agent Agreement (“Warrant Agent Agreement”) between the Company and VStock Transfer, LLC, as warrant agent, dated June 5, 2026.”
EXOZYMES INC. entered into Underwriting Agreement with Public Ventures LLC doing business as MDB Capital valued at Issuance and sale of 592,270 shares of common stock and warrants to purchase up to 296,135 shares of (effective 2026-06-05).
“eXoZymes Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of June 5, 2026, with Public Ventures LLC, doing business as MDB Capital (“MDB”), as the sole underwriter and book runner, pursuant to which the Company issued and sold, in a firm commitment underwritten offering (the “Offering”), an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Common Stock”), of the Company and warrants to purchase up to an additional 296,135 shares of Common Stock (the “Warrants”).”
EXOZYMES INC. entered into Underwriting Agreement with MDB Capital valued at approximately $5,330,430 (effective 2026-06-05).
“On June 5, 2026, eXoZymes Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of June 5, 2026, with MDB Capital (“MDB”), as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering (the “Offering”) an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Common Stock”), of the Company and 292,135 warrants to purchase up to an aggregate of 292,135 shares of Common Stock (the “Warrants”).”
Christopher A. Marlett was appointed as Chairman of the Board at EXOZYMES INC..
“The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.”
Edgardo Rayo was appointed as member of the Board at EXOZYMES INC..
“On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation.”
Mohammad Hayat resigned as President and Chairman at EXOZYMES INC..
“On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors (the “ Board ”) of eXoZymes Inc., a Nevada corporation (the “ Company ”), as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company.”
EXOZYMES INC.: Changed company name from Invizyne Technologies Inc. to eXoZymes Inc. via certificate of amendment to articles of incorporation (effective 2025-02-10).
“On February 10, 2025, Invizyne Technologies Inc. filed a certificate of amendment to its articles of incorporation to change its name to "eXoZymes Inc."”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.